Bloomberg BusinessWeek
(7/27, Edney) reports that Amarin Corp. has received FDA "approval for
its first drug, a treatment to help combat high levels of blood fat
that can lead to stroke and heart attack." The agency "cleared Vascepa
[icosapent ethyl] as an adjunct to diet for a condition known as very
high triglycerides, the company said in a statement."
Reuters (7/27) reports that the drug had previously been called AMR101.
Forbes
(7/27) reports that "The triglyceride-lowering efficacy of Vascepa has
been studied in two 12-week, placebo-controlled phase 3 studies: ANCHOR,
in patients with triglyceride levels between 200 and 500 mg/dl, and
MARINE, in patients with triglyceride levels between 500 and 2000
mg/dl."
No comments:
Post a Comment